Introduction
Glucose and other stimuli cause large dense core insulin-containing vesicles (LDCVs) to move towards, and eventually fuse reversibly with, the plasma membrane in pancreatic islet β-cells (Rutter, 2001; 2004) . We have recently shown that insulin-containing vesicles are transported from the cell centre to the cortex primarily on the microtubule (MT) based motor protein conventional kinesin, also called kinesin I (Varadi et al., 2002; Varadi et al., 2003) . By contrast, the short-range movements in the cortical regions of the cell which carry vesicles over the last few hundred nanometers to the cell surface seem more likely to involve F-actin which is abundant in this region (Nakata and Hirokawa, 1992; Varadi et al., 2003; Tsuboi et al., 2003) . Prime candidates for transport along these filaments are class V myosin motors (Rudolf, 2003; Mermall et al., 1998) . Myosin Va (MyoVa) is composed of two heavy chains which dimerise via a coiled-coil motif located in the stalk region of the heavy chain (Cheney et al., 1993) . The heavy chain contains an amino-terminal, actinbinding motor domain (Cheney et al., 1993) followed by a neck region to which up to six regulatory light chains are bound, and a carboxy-terminal globular domain (Cheney et al., 1993) which is thought to mediate organelle binding specificity (Reck-Peterson et al., 2000) .
Insights into the potential functions of MyoVa have come from several lines of investigation, including identification of organelles and proteins that interact with MyoVa (Reck-Peterson et al., 2000; Karcher et al., 2002; Langford, 2002) . The most powerful strategy has been the phenotypic characterization of lethal alleles of the dilute (MyoVa lethal mutant) mouse and cells derived from them (Mercer et al., 1991) . The dilute mice develop severe seizures and die within three weeks after birth. The primary neuronal defect thought be responsible is the absence of smooth endoplasmic reticulum within the dendritic spines of Purkinje neurons (Takagishi et al., 1996) . Analyses of organelle movement in cultured melanocytes (Provance, Jr. et al., 1996; Wu et al., 1998) , neurons (Bridgman, 1999) and macrophages (Al Haddad et al., 2001 ) from dilute and wild-type mice have also provided evidence for a direct role of MyoVa in both organelle transport and tethering. Moreover, MyoVa has been identified on synaptic vesicles (Evans et al., 1998; Miller and Sheetz, 2000) , and inhibition of myosin ATPase activity reduces neurotransmitter release in brain slices (Prekeris and Terrian, 1997) . In addition, a recent report revealed the role of MyoVa in the distribution of secretory granules in PC12 cells (Rudolf et al., 2003) . Finally, the yeast homologue of MyoV, Myo2p, is involved in secretory vesicle (Schott et al., 1999) peroxisome (Hoepfner et al., 2001) , and vacuole (Ishikawa et al., 2003) transport.
The role of MyoVa in mitochondrial transport is, however, less clear. In vitro motility assay demonstrated that actin-dependent motor activity is associated with mitochondria (Simon et al., 1995) . Immunoelectron microscopy revealed association of MyoVa with the mitochondrial membrane in melanoma cells (Nascimento et al., 1997) . Furthermore, a recent study also described the presence of this motor protein on mitochondria in myoblasts and suggested a role for MyoVa in calcium dependent movements of these organelles (Yi et al., 2004) . In contrast, mitochondrial transport was not affected in cells bearing mutations in either of the genes for myosins I, II and V (DePina and Langford, 1999 ) and a shortening of the lever arm of Myo2p had no effect on mitochondrial morphology, actin organisation or the rate of mitochondrial movement in the mother cell (Boldogh et al., 1998) . On the other hand, Myo2p mutant cells were defective in the segregation of mitochondria (Boldogh et al., 1998 (Boldogh et al., , 2004 Itoh et al., 2002) .
Myosin Va is recruited to the vesicle surface by members of the Rab family of G-proteins (Hume et al., 2002; Provance et al., 2002 , Wu et al., 2002 Fukuda et al., 2002) . This process requires the presence of a rabphilin-like effector protein that bridges the indirect interaction between the Rab protein and myosin Va (Wu et al., 2002; Fukuda et al., 2002) .
In melanocytes, Rab27a binds to the melanosome first and then recruits melanophilin/Slac-2a, a rabphilin-like effector protein, which in turn recruits myosin Va Wu et al., 2002a, b) . In pancreatic β-cells, suppression of Rab27a function impaired insulin exocytosis triggered by secretagogues (Waselle et al., 2003) . β-cells also express a Rab27a effector protein granuphilin-a/SLP4-a which is localised on the membrane of insulin granules (Wang et al., 1999; Yi et al., 2002; Izumi et al., 2003) and its overexpression causes a profound inhibition of deploarisation-induced insulin secretion (Wang et al., 1999; Coppola et al., 2002; Torii et al., 2002) . Granuphilin directly binds to syntaxin 1a Torii et al., 2004) and Munc 18-1 (Coppola et al., 2002) and is thought to be involved in tethering insulin granules to the plasma membrane (Torii et al., 2004) . MyRIP/Slac2c, another Rab27a effector , is also expressed in β-cells and involved in the regulation of insulin release (Waselle et al., 2003) .
However, unlike for Rab27 or its effector proteins, the role of MyoVa in insulin-containing vesicle transport and membrane fusion is not known.
Here, we investigated the involvement of MyoVa in the distribution, motility and exocytosis of insulin containing vesicles in single pancreatic β-cells (MIN6). Inhibition of MyoVa function achieved by RNA interference or over-expression of a dominant negative mutant resulted in clustering of secretory granules, a substantial reduction in the number of vesicles docked at the plasma membrane, and a decrease in the number of single exocytotic events and in global insulin release. These data demonstrate that MyoVa is essential for trafficking secretory organelles in neuroendocrine cells. antibody, DIL2, was raised against a GST-fusion protein containing myosin V heavy chain residues 910 -1,106, which correspond to the first segment of α-helical coiled-coil in the central rod domain (Wu et al., 1998) .
Materials and Methods

Materials
Cell Culture -MIN6 pancreatic β-cells (passages #19-35) were cultured in Dulbecco's modified Eagle's medium (DMEM) tissue-culture medium supplemented with 15% (v/v) foetal calf serum (FCS), penicillin (100 units.ml -1 ), streptomycin (0.1 mg.ml -1 ) and Lglutamine (2 mM) at 37 o C in an atmosphere of humidified air (95%) and CO 2 (5%) as described previously (Molnar et al., 1995) .
Plasmids -A plasmid encoding mitochondrially-targeted Discoidium red fluorescent protein (mito.DsRed) was generated as described earlier (Varadi et al., 2002) . The expression vector MGTD.pEGFP (myosin Va globular tail domain) is described elsewhere (Wu et al., 1998) . Plasmid encoding NPY-targeted monomeric red fluorescent protein (NPY.mRFP) was generated as described earlier (Tsuboi et al., 2003) .
RNA preparation, reverse transcription and PCR -Total RNA from mouse brain, spleen and MIN6 pancreatic β-cells was prepared as described previously (Varadi et al.,1996) . o C for 1 min. The last cycle was followed by a final extension step at 72 o C for 10 min. After PCR, the samples were subjected to electrophoresis in a 1.9 % (w/v) agarose gel containing 0.4 µg ethidium bromide in 1 x TBE buffer (89 mM Tris base, 89 mM boric acid, 2 mM EDTA). For DNA sequencing and restriction enzyme digestion, 100 µl PCR samples were precipitated with ethanol and then fractionated by electrophoresis in 1.3 % (w/v) low-melting-point agarose gels. The separated bands were isolated and the PCR products extracted from the gel slices by Wizard PCR preps DNA purification system (Promega). The primers were designed to flank the alternative spliced forms in the C-terminal tail domain of MyoVa (Seperack et al., 1995) . or empty vectors (pAdTrack-CMV, the latter encodes EGFP) (He et al., 1998) Immunocytochemistry was performed as described earlier (Varadi and Rutter, 2002) and then images were captured on an UltraVIEW™ confocal microscope (Varadi et al., 2004) .
Total internal reflection fluorescence (TIRF) microscopy -Cells were imaged in KRH buffer initially at 3 mM then at 30 mM glucose. Incubations were performed on a thermostaticallycontrolled (37 o C) stage of an Olympus IX-70 microscope (Olympus UK) fitted with a high numerical aperture objective lens (Apochromatic, 100X, NA = 1.65, infinity corrected, Olympus). To assess the dynamics ofNPY.mRFP, we employed a TIRF microscope (Till Photonics, Munich) as described previously (Tsuboi et al., 2000; Pinton et al., 2002; Tsuboi and Rutter, 2003 (Grynkiewicz et al., 1985) using a Leica DM-IRBI inverted microscope (x40 objective) and a Hamamatsu C4742-995 charged-coupled device camera driven by OpenLab MT software (Improvision, Coventry, U.K.) (Varadi and Rutter, 2002) .
Silencing of endogenous myosin Va expression with small interfering RNAs -Sequences
corresponding to the mouse myosin Va cDNA (Strobel et al., 1990) ; (a.) 2390 -2410; 5'-AAGAGATACCTGTGTATGCAG-3'; b.) 2507 -2528; 5'-AAGTACTGGCGCATGTATGTG-3') were used as targets for siRNA. The following siRNAs were used as controls: a.) 5'-AAGTGTGCAACCATGTGAATG-3'; b.) 5'-AAGTGGTTGGCGATTACCGAT-3'. These sequences showed no significant homology to any other gene known analyzed using BLAST search. siRNAs were synthesized by in vitro transcription using the Silencer TM siRNA Construction Kit (Ambion Inc., Austin, TX USA). MIN6 cells were transfected with 60 pmol siRNA duplex using 3 µl Oligofectamine TM (Invitrogen) in growth medium without antibiotics or serum for 5 h (Varadi et al., 2003) . Whole cell lysate was prepared 24, 48, 72 and 96 h after transfection. Cell lysate (10 µg) from siRNA and control RNA transfected cells were separated on a 9 % polyacrylamide gel then blotted onto Immobilon-P transfer membrane and probed with a rabbit polyclonal anti-myosin Va antibody and a mosue monoclonal anti-tubulin antibody. The blots were scanned and quantified with NIH ImageJ software (http://rsb.info.nih.gov/ij/).
Assay of insulin release -MIN6 cells were seeded at a density of 4 -6 x 10 5 .ml -1 on 24-mm-diameter poly-L-lysine-coated coverslips, and cultured overnight. Cells were transfected with siRNAs as described above. The cells were cultured for 48 h and insulin release was stimulated and assayed as described earlier (Varadi et al., 2002) using Mercodia Ultrasentive Mouse Insulin ELISA Kit (Mercodia AB, Uppsala, Sweden). First, we investigated the expression of MyoVa mRNA in MIN6 β-cells by using RT-PCR.
Subcellular fractionation using OptiPrep
A strategy was used by which the four different alternatively spliced isoforms of MyoVa could be identified (Fig. 1 A; 
-B+D+F; -B+D-F; -B-D+F and +B-D-F). Spleen is known to
express three splice variants of MyoVa (Fig. 1 A; -B+D+F; -B+D-F; -B-D+F; Huang et al., 1998a, b; Au and Huang, 2002; Seperack et al., 1995) . The forth, shortest splice form excluding both exons D and F is expressed in brain (Fig. 1 A; +B-D-F; Huang et al., 1998a, b; Au and Huang, 2002; Seperack et al., 1995; ) . Similar to brain and other neuroendocrine cells (Nagashima et al., 2002; Seperack et al. 1995; Wu et al., 2002) , MIN6 β-cells expressed only the +B-D-F splice variant (Fig. 1 A) . Immunoblot analysis revealed that
MyoVa is present at the protein level in both MIN6 β-cells and primary rat islets of Langerhans ( Fig. 1 B) . Using double-immunofluorescent microscopy, MyoVa was localised principally on insulin-positive structures in both MIN6 cells ( Fig. 1 C, zoomed in regions, arrowheads) and in primary rat β-cells (data not shown).
To assess the proportion of cellular MyoVa which was stably associated with LDCVs, we next explored the behaviour of MyoVa and other organelle markers upon density gradient fractionation of extracts from clonal MIN6 β-cells. Secretory granules were enriched from the post nuclear supernatant by differential centrifugation and subsequently loaded onto a continuous OptiPrep MT density gradient to separate the vesicular components according to their buoyant density. The obtained gradient fractions were analysed by immunoblotting to determine the distribution of MyoVa (MyoVa, Fig. 2 A) , glycerol phosphate dehydrogenase (mGPDH; a marker protein for mitochondria, Fig. 2 A) , phogrin (LDCV membranes) (Wasmeier and Hutton, 1996; Pouli et al., 1998) ; trans-Golgi network protein 38 (TGN38, Golgi) (Luzio et al., 1990) ; insulin receptor (plasma membrane, PM); mannose-6-phosphate receptor (lysosomes), and sterol regulatory element binding protein 1c
precursor ( colocalisation of phogrin-EGFP and insulin in this cell type (Pouli et al., 1998; Varadi et al., 2002; Tsuboi and Rutter, 2003) . FACS-purified phogrin-EGFP-labelled particles were positive for both insulin (Fig. 2 B , a-c) and MyoVa (Fig. 2 B, d-f ) and the apparent dimensions of the doubly labelled structures (200-500 nm) corresponded closely with those of dense-core secretory vesicles (Fig. 2 B) (Bonner-Weir, 1988) , at least at the limit of light microscopy. To eliminate the possibility that the MyoVa antibody non-specifically cross-reacted with insulin when used for immunocytochemistry we precipitated the FACS sorted vesicles with trichloracetic acid, immunoblotted and then probed with the MyoVa specific antibody. This antibody recognised MyoVa with the correct molecular weight in these samples (Fig. 2 B, arrow) . Together, the three complimentary approaches used above support the view that the majority of MyoVa is associated with insulin-containing granules in β-cells.
Expression of the MyoVa tail domain leads to clustering of insulin containing
vesicles -To test whether inhibition of the motor activity of MyoVa leads to reduction in motility and distribution of insulin-containing vesicles, we transfected a C-terminal tail fragment of MyoVa, MGTD.EGFP, into β-cells. This tail fragment is known to act as a potent inhibitor of MyoVa function in mouse melanocytes (Wu et al., 1998) and PC12 cells (Rudolf et al., 2003) . We labelled insulin-containing vesicles by expressing cDNA encoding neuropeptide Y fused to monomeric red fluorescent protein (NPY.mRFP), a construct which is targeted efficiently to LDCVs (Tsuboi and Rutter, 2003) . Whilst in control cells labelled secretory vesicles were evenly distributed and frequently seen at the cell periphery (Fig. 3 a-d ) expression of the MyoVa tail fragment led to vesicle clustering and exclusion from the cell cortex (Fig. 3 e-h, 4 a-d) . If MGTD.EGFP directly interacted with secretory granules then we expected to observe an increased local concentration of MGTD.EGFP in the clusters of fluorescent secretory vesicles. As anticipated, MGTD.EGFP also showed strong clustering (Fig. 3 f) and high, though not complete, colocalisation with the accumulated red fluorescence of vesicles (Fig. 3 g, h) . The observed formation of clusters is likely to involve both a block of transport of LDCVs to the actin cortex and/or a change in tethering: both phenomena have previously been observed for melanosomes in melanocytes expressing the tail fragment of MyoVa, and are also apparent in melanocytes from dilute mice which carry a homozygous mutation in the MyoVa gene (Wu et al., 1998) .
In cells where more moderate clustering was apparent we were able to show clear colocalisation of single vesicles with MGTD.EGFP (Fig. 4. A, a-d, Fig4Acvideo1 .mov).
Whilst it was not feasible to analyse individual vesicle movements in cells where intense clustering was seen (Fig. 3) 
Impact of MyoVa inhibition on mitochondrial movements and the cytoskeleton -In
contrast to the situation with LDCVs, coexpression of MGTD.EGFP with Mito.DsRed did not induce any clustering of mitochondria (Fig. 4 C. ) and the majority of the expressed MGTD.EGFP failed to localise with these organelles (Fig. 4 C, d-f) . Moreover, the movement of individual mitochondria was not affected by expression of MGTD.EGFP (Fig.   4 D, C) . Thus, rapid movements of MGTD.EGFP were observed which did not coincide with those of the separately-labelled mitochondria (Fig. 4 D) .
In order to eliminate the possibility that the clustering of LDCVs observed above may be due to altered organisation of actin filaments and/or microtubules, we visualised these cytoskeletal structures in control and MGTD.EGFP-expressing cells. As anticipated given the normal mitochondrial distribution and motility, no apparent effect of MGTD.EGFP was observed on the structure and organisation of actin and tubulin networks (not shown). In MIN6 cells, strong phalloidin staining was observed predominantly at the cortical regions while tubulin extended from the perinuclear region to the cortex (not shown). As expected, a small proportion of vesicles, probably those which were docked at the plasma membrane, clearly localised close to the phalloidin-positive F-actin cortex (data not shown). The above data suggest that the expression of tail fragment of MyoVa does not inhibit cellular membrane traffic in general but is selective for MyoVa associated organelles and interferes with their F-actin-dependent transport in the cortex.
Silencing of MyoVa by RNA interference, or expression of the MyoVa tail domain,
reduces the number of secretory vesicles docked at the plasma membrane, the number of exocytotic events, and insulin release provoked by glucose -In order to confirm and further quantitate the change in the number of vesicles at the cortex after inhibition of MyoVa with MGTD.EGFP (Fig. 3, 4 ) we visualised vesicles within ~ 100 nm of the plasma membrane using total internal reflection of fluorescence (TIRF) microscopy (Axelrod, 1981; Tsuboi et al., 2000) . We first counted the number of plasma membraneassociated vesicles in a 200 µm 2 area. This revealed that MGTD.EGFP overexpression significantly reduced (by 52.6 %) the number of plasma membrane-docked vesicles (Fig. 5 A, B (Fig. 5 D) .
In order to avoid potential non-specific effects of overexpression of MGTD.EGFP, and to permit measurements of insulin secretion in cell populations, we used RNA interference (Elbashir et al., 2001) to silence endogenous MyoVa expression in MIN6 β-cells (Varadi et al., 2003; daSilvaXavier et al., 2004) . We targeted two regions of mouse MyoVa cDNA (see Methods) and found that both of the siRNA duplexes tested reduced the total MyoVa expression by at least 40 %. However the siRNA pair corresponding to 2390-2410 bp was more effective and reduced the total MyoVa expression by 55 ± 5 % with respect to a scrambled oligonucleotide duplex; this siRNA was used in the experiments presented in Fig. 6 . In MyoVa-silenced cells we found similar vesicle clustering as observed following MGTD.EGFP expression (Fig. 6 B c, d versus a, b; n = 315 cells in five independent experiments; n = 85 and 230 similar to those of image c and d, respectively), whilst significant clustering of LDCVs was not detected in control cells (Fig. 6 B, a-b , n = 267 cells in five independent experiments).
As expected from previous transfection experiments in MIN6 cells (Varadi et al., 2002) , the siRNA suppression of MyoVa protein expression was heterogeneous (Fig. 6 C) . Thus, in 30-40 % of the siRNA treated cells endogenous MyoVa protein was no longer detectable (Fig 6 C, arrows) . By contrast, in the remainder of the cells, MyoVa expression was suppressed by 50-80 %. We co-stained the cells for tubulin in order to eliminate the possibility that the observed reduction in MyoVa expression could be a result of uneven immunostaining. Excluding this possibility, tubulin staining was equally strong in the siRNA treated cells as in control cells.
Insulin release was measured from MyoVa-silenced and control cells using an insulin ELISA assay (see Methods). In order to investigate the effect of reduced MyoVa activity on the size of the readily releasable / docked vesicle pool (Bratanova-Tochkova et al., 2002; Rutter, 2004) , we stimulated cells with KCl. Suppression of MyoVa activity lead to a 29 ± 3.4 % decrease in the number of release events compared to control cells (Fig. 7 A) .
Similarly, glucose-stimulated insulin release, expected to reflect release of LDCVs from both a readily-releasable and reserve pool, was also significantly reduced by 28 ± 5.7 % (Fig. 7 B) . These data are in agreement with those obtained by TIRF imaging, bearing in 
Discussion
MyoVa is a mediator of dense core vesicle movement and insulin secretion-We provide here morphological and biochemical evidence that, in pancreatic β-cells, a convenient neuoroendocrine cell model, MyoVa is (a) associated principally with secretory granules (Fig. 1, 2 ) and (b) transports these within the F-actin-rich cortex towards the plasma membrane. Thus, we show that suppression of MyoVa activity, achieved by two distinct means (use of a dominant-negative or RNAi) leads to clustering of vesicles and to a reduction in their cortical localisation (Figs 3, 4, 6, Fig4Acvideo1.mov) . Although similar phenomena were reported recently in PC12 cells (Rudolf et al., 2003) the present report now provides functional data to demonstrate that changes in vesicle distribution are accompanied by a significant reduction in the number of depolarisation-stimulated exocytotic events and insulin release (Figs 5, 7, Fig5avideo3.mov, Fig5bvideo4.mov) . In this way, we show that MyoVa-driven movements of vesicles along the cortical actin network are required for the terminal stages of regulated exocytosis.
In the present study, long excursions of individual LDCVs, likely to be dependent upon MTs (Pouli et al., 1998; Varadi et al., 2003) were observed in both dominant-negative MyoVa tail domain-expressing (Fig. 4) and siRNA-silenced cells. This finding suggests that MT-dependent transport is unlikely to be strongly affected by the inactivation of MyoVa.
Moreover, no apparent effect of expression of the dominant tail domain was observed on the structure and organisation of the actin or tubulin networks (data not shown).
Nevertheless, we cannot rule out the possibility that inhibition of Myo Va may have some impact on MT-dependent transport or structure (Weber et al., 2004) . Furthermore, a recent report revealed that indeed MyoVa can mechanochemically couple MTs to F-actin in vitro (Cao et al., 2004) and implicated the tail domain in MT binding (Cao et al., 2004) .
Role of MyoVa in controlling mitochondrial movements-In contrast to the situation
with LDCVs, we found no effect of inhibiting MyoVa activity on mitochondrial morphology or movement (Fig. 4) . In agreement with this observation, mitochondrial transport was not affected in cells bearing mutations in the genes for myosins I, II and V (DePina and Langford, 1999) . Furthermore, shortening of the lever arm of Myo2p, the mammalian homologue of myosin V in S. cerevisiae, had no effect on mitochondrial morphology, actin organisation or the rate of mitochondrial movement in the mother cell (Boldogh et al., 1998) , thus arguing against the role of MyoVa in mitochondrial motility during interphase.
On the other hand, Myo2p mutant cells were defective in the segregation of mitochondria (Boldogh et al., 1998) , suggesting that myosin family members may participate in mitochondrial movements under some circumstances, including mitosis. Furthermore, the results presented here do not support the model proposed recently by Hajnoczky and coworkers (Yi et al., 2004) in which MyoVa was suggested to be on mitochondrial membranes and involved in the Ca 2+ -dependent control of mitochondrial motility.
Potential mechanisms of MyoVa recruitment to LDVCs-The finding of actin-based motor-dependent transport of secretory vesicles, together with previous observations
showing an MT-dependent movement of secretory vesicles to the plasma membrane (Pouli et al., 1998; Varadi et al., 2002; Varadi et al., 2003) , provides strong evidence for the existence of a dual transport system used by LDCVs, which is likely to be dependent upon the localisation of the vesicle within the cell. Evidence for such a dual transport system has also been provided for melanosomes (Reck-Peterson et al., 2000) , the endoplasmic reticulum (Tabb et al., 1998; Reck-Peterson et al., 2000) and phagosomes (Al Haddad et 22 al., 2001) . Indeed, it appears that motor proteins associated with the surface of organelles are often organised into protein complexes (Schliwa, 1999) . For example, a direct interaction between microtubule-and actin-based transport motors has been shown for the mouse ubiquitous kinesin heavy chain and MyoVa (Huang et al., 1999) . Although the interaction between MyoVa and kinesin heavy chain might coordinate transport in several different ways, one appealing model (Huang et al., 1999) proposes that MyoVa and kinesin bind to the same cargo, as well as to each other, to form an integrated motor complex. In this model, the activity of the complex is tightly regulated such that only one motor in the complex is significantly active at any given time. The evident advantage of such a motor complex is that it may allow a single vesicle to be transported by multiple motors and to move on both MT and actin tracks. A vesicle thus equipped with multiple motors might thus make the transition from MT to actin filaments easily by switching between motor activities. In MT-rich cellular domains, it seems likely that kinesin activity would lead to long-range MT-based movement (Pouli et al., 1998; Varadi et al., 2002; Varadi et al., 2003) , whereas in regions such as the cellular cortex, where MTs are rare or absent, MyoVa would take over to deliver cargo to its final destination.
It is intriguing to ask how these complexes might be recruited to, and regulated on, LDCVs. Whilst kinectin is thought to mediate the binding of kinesin I to membranes (Vallee and Sheetz, 1996) , more recent reports suggest that kinesin I binds to cargoes via a set of proteins, JIP-1, JIP-2 and JIP-3, also involved in intracellular signaling (Bowman et al., 2000; Verhey et al., 2001) . For MyoVa, cytoplasmic domain of synaptobrevinsynaptophysin complex has been proposed to function as a binding partner on small synaptic vesicles (Prekeris and Terrian, 1997) . On the other hand the small monomeric Gprotein family member, Rab27a, has been implicated in the interaction between melenosomes and MyoVa (Deacon and Gelfand, 2001 ) in a receptor-motor complex including the Rab27a binding protein melanophilin, a bridging protein with strong similarity to the Rab3a effector protein, rabphilin (Matesic et al., 2001) .
The interaction between melanophilin and MyoVa has been shown to be regulated by a melanocyte-specific alternative splicing in the tail domain of MyoVa. In MyoVa, alternative splicing takes place between exons A and G (Fig 1 A) with four alternatively spliced iso forms containing different combinations of exons B, D, and F being identified , Seperack et al., 1995 . The presence of exon F, an alternatively spliced exon expressed in melanocytes but not in neuroendocrine cells, is required for MyoVa to localise to melanosomes (Nagashima et al., 2002; Seperack et al. 1995; Wu et al., 2002,Fukuda and Kuroda 2003) . In addition, the globular tail domain is also required for melanophilin-MyoVa interaction (Wu et al., 2002, Fukada and Kuroda 2003) . In PC12 cells, over-expression of a tail fragment containing exon F did not target to vesicular structures. However, the expression of exon B was required for the localisation of MyoVa to vesicle structures in this neuroendocrine cell (Au and Huang, 2002) . In agreement with these results, we found that the neuronal splice variant containing exon B but missing exons D and F is expressed in β-cells.
Given the above, it seems likely that exon B and the globular tail domain of MyoVa are involved in the interaction with a Rab effector protein in β-cells as described in melanosomes. However, the composition of the organelle receptor complex may well be different in the two cell types. Thus, Rab27a and MyRIP have been implicated in the regulation of exocytosis in pancreatic β-cells and neuroendocrine PC12 cells (Waselle et al., 2003 , Desnos et al., 2003 . However, the Rab27/MyRIP protein complex does not appear to require recruitment of myosin on the secretory granules for function (Waselle et al., 2003) . The association of myosin Va and Rab27/MyRIP has not been demonstrated in vivo, although it contributes to the cytoplasmic distribution of secretory granules in PC12 cells (Rudolf et al., 2003) . Might other members of the Rab family be involved in binding MyoVa to vesicles? Rab3a is known to be specifically associated with small synaptic vesicles and insulin granules (Regazzi et al., 1996) and thus may have a role, a view supported by the fact that Rab3a -/-mice develop of hyperglycaemia and insulin secretory deficiencies (Yaekura et al., 2003) . Further studies will be necessary to distinguish between these possibilities, and to explore the mechanisms whereby increases in glucose concentration might lead to the recruitment of MyoVa to LDCVs in insulin-secreting cells.
Torii, S., Takeuchi, T., Nagamatsu, S., Izumi, T. (2004) The structure of the possible alternative spliced forms is shown at the top. The capital letters represent exons as described previously (Seperack et al., 1995) . at 25 frames/second. Video 4 show a zoomed in region from video 3 as indicated on the still images (Fig. 3) . 
